Abalos Therapeutics Publishes Preclinical Data for Novel Arenavirus-Based Cancer Immunotherapy ABX-001
核心洞察
Abalos Therapeutics (搜索) published preclinical proof-of-concept data for ABX-001 in Cell Reports Medicine, demonstrating the first-in-class arenavirus-based immunotherapy's potential to overcome current immunotherapy limitations.
ABX-001 showed strong anti-tumor efficacy in murine solid tumor models by inducing tumor-specific T cell expansion and achieving complete tumor remission with long-lasting immunity protection.
The therapy demonstrated a favorable safety profile in both arenavirus-susceptible mice and non-human primates, with no adverse effects observed despite strong immune activation.
Abalos Therapeutics (搜索) announced the publication of preclinical proof-of-concept data for its immunoactivating lead candidate ABX-001 in Cell Reports Medicine, marking a significant milestone for the company's first-in-class approach to cancer immunotherapy. The publication highlights ABX-001's potential as a powerful new drug class that systemically activates both innate and adaptive immune responses with a single administration.
Novel Arenavirus-Based Approach
The publication titled "Optimized arenavirus design with tumor-tropic mutations promote safety and anti-tumor efficacy via sustainable immune modulatory properties" provides comprehensive data on ABX-001, the first drug candidate leveraging Abalos' proprietary AdaptInnate approach. The company developed ABX-001 by optimizing a non-lytic arenavirus strain through strategic selection of specific mutations for immunostimulatory and anti-tumoral properties, including high tumor-tropism and minimal replication in healthy cells.
ABX-001's mode of action is characterized by persistent and sustained replication in cancerous and antigen-presenting cells without destroying them. This results in exceptional induction of effector T-cells and actively guides immune cells into the tumor. The novel, non-oncolytic approach for systemic use is designed to induce targeted, effective, and durable anti-cancer activity against primary tumors and metastases.
"The publication in Cell Reports Medicine underscores the potential of our novel anti-cancer approach as a promising alternative for patients who face the limitations of current immunotherapies," said Jörg Vollmer, CSO at Abalos. "By safely engaging all major lymphatic organs in a coordinated, body-wide attack against tumors, we aim to overcome key challenges such as immune evasion of cancer cells, inadequate T cell activation, and tumor heterogeneity."
Preclinical Efficacy and Safety Results
In various murine solid tumor models, ABX-001 exhibited strong anti-tumoral efficacy by inducing the expansion of tumor-specific T cells and immune-activating cytokines such as IFN-γ (搜索). Notably, mice with complete tumor remission upon systemic ABX-001 treatment were protected from tumor cell re-challenge, suggesting long-lasting anti-tumoral immunity.
The candidate demonstrated a favorable safety profile, with minimal viral replication in healthy tissues and no severe disease symptoms in arenavirus-susceptible mice. The results were replicated in non-human primates highly sensitive to wildtype arenaviruses. Treatment with ABX-001 led to substantially increased levels of immunostimulatory cytokines and chemokines as well as significantly increased expansion of monocytes, CD4+ and CD8+ T cells.
The CD4+/CD8+ ratio decreased after ABX-001 application, reflecting the strong priming of cytotoxic T cells triggered by the candidate. Despite this strong immune activation, no adverse effects were observed at any dose level or timepoint, demonstrating a highly favorable safety profile.
Clinical Development and Conference Presentation
Based on the encouraging preclinical proof-of-concept data, Abalos is advancing ABX-001 into a Phase 1 first-in-human basket-style trial across sites in Europe. The first-in-human trial is expected to begin soon, according to company statements.
Data on ABX-001's development and demonstrated proprietary anti-tumoral efficacy will be presented at the European Society for Medical Oncology (ESMO) Congress 2025. The poster presentation, titled "Optimized arenavirus design with tumor-tropic mutations accelerates anti-tumor efficacy of lymphocytic choriomeningitis sustainable immune modulatory properties," will be presented by Prof. Karl S Lang, PhD, Chair of Immunology at the Medical Faculty, University Duisburg-Essen and Scientific Founder of Abalos, on Monday, October 20, 2025.
Vollmer noted that the strong safety profile and robust anti-cancer activity demonstrated across a range of clinically relevant solid tumor models provide a solid foundation for the clinical development of ABX-001. The company's goal is to establish a new drug class in immuno-oncology by directing the full breadth of the immune system's power specifically towards cancer cells.